The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
371
Brepocitinib PO QD
Placebo PO QD
Time to treatment failure on or after Period 1 Week 6 up to Period 1 Week 48
Time frame: 48 weeks
Proportion of participants meeting treatment failure criteria on or after Period 1 Week 6 up to Period 1 Week 24
Time frame: 24 weeks
Change in logMAR BCVA in each eye from best state achieved at or prior to Period 1 Week 6 up to Period 1 Week 24
Time frame: 24 weeks
Change in central subfield thickness from best state achieved in each eye at or prior to Period 1 Week 6 up to Period 1 Week 24
Time frame: 24 weeks
Change in logMAR BCVA in each eye from best state achieved at or prior to Period 1 Week 6 up to Period 1 Week 48
Time frame: 48 Weeks
Change in central subfield thickness from best state achieved in each eye at or prior to Period 1 Week 6 up to Period 1 Week 48
Time frame: 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Bakersfield, California, United States
Clinical Trial Site
Beverly Hills, California, United States
Clinical Trial Site
Fullerton, California, United States
Clinical Trial Site
Irvine, California, United States
Clinical Trial Site
La Jolla, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Modesto, California, United States
...and 97 more locations